In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy
暂无分享,去创建一个
[1] S. Thomas,et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy , 2020, Science Translational Medicine.
[2] Zhuang Liu,et al. In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery , 2019, Advanced Functional Materials.
[3] Kyung Soo Park,et al. Cancer nanomedicine for combination cancer immunotherapy , 2019, Nature Reviews Materials.
[4] Jihoon Kim,et al. Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. , 2019, Acta biomaterialia.
[5] Hao Cheng,et al. A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade , 2019, Advanced materials.
[6] Weikang Hu,et al. Advances in crosslinking strategies of biomedical hydrogels. , 2019, Biomaterials science.
[7] Y. Lim,et al. Degradation‐Regulatable Architectured Implantable Macroporous Scaffold for the Spatiotemporal Modulation of Immunosuppressive Microenvironment and Enhanced Combination Cancer Immunotherapy , 2018, Advanced Functional Materials.
[8] Quanyin Hu,et al. Delivery Strategies for Immune Checkpoint Blockade , 2018, Advanced healthcare materials.
[9] Zhen Gu,et al. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade , 2018, Advanced materials.
[10] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[11] Zhuang Liu,et al. In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy , 2018, Science Translational Medicine.
[12] Huadan Xue,et al. Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments. , 2018, Cancer letters.
[13] V. Engelhard,et al. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity , 2018, The Journal of Immunology.
[14] Gordon J. Freeman,et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity , 2017, Nature Communications.
[15] Huadan Xue,et al. Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-64Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. , 2017, Molecular pharmaceutics.
[16] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[17] Mark R Prausnitz,et al. Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. , 2017, Annual review of chemical and biomolecular engineering.
[18] S. Thomas,et al. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy , 2017, Advanced drug delivery reviews.
[19] Yanan Cui,et al. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system , 2017, Drug development and industrial pharmacy.
[20] David J. Mooney,et al. Designing hydrogels for controlled drug delivery. , 2016, Nature reviews. Materials.
[21] Zhen Gu,et al. Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody , 2016, Advanced materials.
[22] Quanyin Hu,et al. Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors. , 2016, ACS nano.
[23] K. Thurecht,et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.
[24] Zhen Gu,et al. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. , 2016, Nano letters.
[25] Nikhil S. Joshi,et al. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.
[26] Won Jong Kim,et al. Enhanced tumor-targeted gene delivery by bioreducible polyethylenimine tethering EGFR divalent ligands. , 2015, Biomaterials science.
[27] C. Jackisch,et al. Subcutaneous Administration of Monoclonal Antibodies in Oncology. , 2014, Geburtshilfe und Frauenheilkunde.
[28] H. Kohrt,et al. Intratumoral Immunization: A New Paradigm for Cancer Therapy , 2014, Clinical Cancer Research.
[29] F. Hourcade‐Potelleret,et al. Development of a Subcutaneous Formulation for Trastuzumab – Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen , 2012, Arzneimittelforschung/Drug Research.
[30] D. Mager,et al. Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in Rats , 2012, Pharmaceutical Research.
[31] Won Jong Kim,et al. NONOates--polyethylenimine hydrogel for controlled nitric oxide release and cell proliferation modulation. , 2011, Bioconjugate chemistry.
[32] Chaoliang He,et al. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[33] R. Vile,et al. Intratumoral immunotherapy: using the tumour against itself , 2005, Immunology.
[34] Michael S. Kuhns,et al. CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.
[35] Y. Zamzam,et al. Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II & III Breast Cancer , 2018 .